|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Sankyo Pharma Gmbh |
|---|---|
| Information provided by: | Daiichi Sankyo Inc. |
| ClinicalTrials.gov Identifier: | NCT00362960 |
Purpose
Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Mellitus Diabetic Nephropathy Proteinuria Renal Disease |
Drug: Olmesartan medoxomil Drug: Losartan |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy |
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2003 |
| Estimated Study Completion Date: | September 2004 |
Eligibility| Ages Eligible for Study: | 30 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Czech Republic | |
| Frydlant v Cechach, Czech Republic | |
| Prague, Czech Republic | |
| Liberec, Czech Republic | |
| Estonia | |
| Tartu, Estonia | |
| Germany | |
| Greifenstein-Beilstein, Germany | |
| Hannover, Germany | |
| Augsburg, Germany | |
| Netherlands | |
| Zwijndrecht, Netherlands | |
| Poland | |
| Warsaw, Poland | |
| Wroclaw, Poland | |
| Grodzisk Mazowiecki, Poland | |
| Watlack, Poland | |
| Wolomin, Poland | |
| Krakow, Poland | |
| Pruszkow, Poland | |
| Torun, Poland | |
| Poznan, Poland | |
| Plock, Poland | |
| Slovakia | |
| Kosice, Slovakia | |
| Sahy, Slovakia | |
| Martin, Slovakia | |
| Lucenec, Slovakia | |
| Nove Zamky, Slovakia | |
| Banska Bystrica, Slovakia | |
| Nitra, Slovakia | |
| Spain | |
| Madrid, Spain | |
| Barcelona, Spain | |
| Principal Investigator: | H Haller, MD | Hanover Medical School |
More Information
| Study ID Numbers: | SE-866/29 |
| Study First Received: | August 10, 2006 |
| Last Updated: | October 6, 2006 |
| ClinicalTrials.gov Identifier: | NCT00362960 History of Changes |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
Type 2 Diabetes Mellitus Diabetic Nephropathy Inflammatory Markers Proteinuria Renal Disease |
|
Losartan Diabetic Nephropathies Metabolic Diseases Molecular Mechanisms of Pharmacological Action Urination Disorders Diabetes Mellitus Endocrine System Diseases Olmesartan medoxomil Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Angiotensin II Type 1 Receptor Blockers Urological Manifestations Signs and Symptoms Proteinuria Urologic Diseases Therapeutic Uses Diabetes Mellitus, Type 2 Anti-Arrhythmia Agents Kidney Diseases Glucose Metabolism Disorders Diabetes Complications |